ArticleClinical and vaccine immunology : CVI2015
Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity.
Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development.The Journal of infectious diseases · 2020Trial
- Characterization of high affinity IgM and IgG monoclonal antibodies against norovirus variants GII.4 and GII.17.Protein science : a publication of the Protein Society · 2026Article
- Structural analyses of the GI.4 norovirus by cryo-electron microscopy and X-ray crystallography revealing binding sites for human monoclonal antibodies.Journal of virology · 2024Article
- Review
- Norovirus Infection in Young Nicaraguan Children Induces Durable and Genotype-Specific Antibody Immunity.Viruses · 2022Article
- Epidemiology and evolution of Norovirus in China.Human vaccines & immunotherapeutics · 2021Review
- Antigenic Diversity of Human Norovirus Capsid Proteins Based on the Cross-Reactivities of Their Antisera.Pathogens (Basel, Switzerland) · 2021Article
- Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses.Nature communications · 2021Article
- The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.Journal of medical virology · 2021Article
- Birth Cohort Studies: Toward Understanding Protective Immunity to Human Noroviruses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Development and Application of a Novel Rapid and Throughput Method for Broad-Spectrum Anti-Foodborne Norovirus Antibody Testing.Frontiers in microbiology · 2021Article
- Review
- Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses.Gastroenterology · 2018Article
- Viral gastroenteritis.Lancet (London, England) · 2018Review
- Prospects and Challenges in the Development of a Norovirus Vaccine.Clinical therapeutics · 2017Review
- Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades.Journal of virology · 2017Article
- Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.PloS one · 2017Article
- Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.PLoS pathogens · 2017Article
- Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Antiviral targets of human noroviruses.Current opinion in virology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The human noroviruses (NoVs) are genetically diverse, rapidly evolving RNA viruses and are the major cause of epidemic gastroenteritis of humans. Serum antibodies that block the interaction of NoVs and NoV viruslike particles (VLPs) with host attachment factors are considered surrogate neutralizing antibodies in the absence of cell culture and small-animal replication models for the human NoVs. A serological assay for NoV-blocking antibodies was used to assess the breadth of the heterotypic antibody response in the context of an experimental challenge study with a human NoV. Heterotypic histo-blood group antigen (HBGA)-blocking activity against GI.4, GI.7, and GII.4 NoVs increased significantly in the serum of individuals (n = 18) infected with Norwalk virus (GI.1). Although the fold increases and peak titers of heterotypic antibody were more modest than titers of antibody reactive with the challenge antigen, Norwalk virus infection elicited a serological rise even against the novel Sydney variant of GII.4 NoVs. These observations indicate that the development of a broadly cross-protective NoV vaccine containing a limited number of genotypes may be possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.